Kiora Pharmaceuticals (NASDAQ: KPRX – Get a rating) is one of 939 publicly traded companies in the Pharmaceutical Preparations sector, but how does it compare to its competitors? We’ll compare Kiora Pharmaceuticals to similar companies based on earnings strength, dividends, institutional ownership, risk, valuation, profitability, and analyst recommendations.
Benefits and evaluation
This table compares the revenue, earnings per share, and valuation of Kiora Pharmaceuticals and its competitors.
| Gross revenue | Net revenue | Price/earnings ratio | |
| Kiora Pharmaceuticals | $10,000.00 | -$16.40 million | -0.28 |
| Competitors of Kiora Pharmaceuticals | $1.86 billion | $249.36 million | -1.48 |
Kiora Pharmaceuticals’ competitors have higher revenues and profits than Kiora Pharmaceuticals. Kiora Pharmaceuticals trades at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
29.7% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 45.3% of the shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 58.2% of the shares of Kiora Pharmaceuticals are held by insiders of the company. In comparison, 14.9% of the shares of all “Pharmaceutical Preparations” companies are held by insiders of the company. Strong institutional ownership indicates that large fund managers, hedge funds, and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Kiora Pharmaceuticals has a beta of 0.94, suggesting its stock price is 6% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals’ competitors have a beta of 1.12, suggesting its stock price average is 12% more volatile than the S&P 500. .
Profitability
This table compares the net margins, return on equity and return on assets of Kiora Pharmaceuticals and its competitors.
| Net margins | Return on equity | return on assets | |
| Kiora Pharmaceuticals | N / A | -131.92% | -79.71% |
| Competitors of Kiora Pharmaceuticals | -3,160.46% | -1,570.05% | -9.52% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Kiora Pharmaceuticals and its competitors, as provided by MarketBeat.com.
| Sales Ratings | Hold odds | Buy reviews | Strong buy odds | Rating | |
| Kiora Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
| Competitors of Kiora Pharmaceuticals | 6393 | 21052 | 43275 | 870 | 2.54 |
Kiora Pharmaceuticals currently has a consensus target price of $2.75, suggesting a potential upside of 550.12%. As a group, the “Pharmaceutical preparations” companies have an upside potential of 134.56%. Given Kiora Pharmaceuticals’ higher consensus rating and higher likely upside potential, equity research analysts clearly believe that Kiora Pharmaceuticals is more favorable than its competitors.
Summary
Kiora Pharmaceuticals beats its competitors on 7 of the 13 factors compared.
About Kiora Pharmaceuticals (Get a rating)
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potentially vision-restoring small molecule, which is in a Phase 1 clinical trial and acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. age. The company is also developing KIO-101, an eye drop in phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for the treatment of non-infectious posterior uveitis; and KIO-201, an eye drop, which is in a Phase 3 clinical trial for the treatment of patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Get news and reviews for Kiora Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com’s FREE daily newsletter.
Comments are closed.